Cancer Research UK logo.
SearchDonate
  • Search

A trial of Veregen cream for women with vulval intraepithelial neoplasia (EPIVIN)

Overview

Cancer types:

Vulval cancer

Status:

Results

Phase:

Phase 2

Details

This trial was looking at Veregen cream to treat pre cancerous changes to the skin of the vulva.

Vulval intraepithelial neoplasia (VIN) means there are pre cancerous changes to cells in the skin of the vulva. It is not cancer, but if it isn’t treated it can develop into vulval cancer. There are 3 categories of VIN. This trial was for women with VIN 3, which means the cells are very abnormal. Your doctor may also call this severe dysplasia.

This trial was open for people to join between 2014 and 2017. The team published the results in 2020.

Recruitment start: 18 September 2014

Recruitment end: 9 June 2017

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor David Luesley

Supported by

NIHR Clinical Research Network: Cancer

University of Birmingham

Sandwell and West Birmingham Hospitals NHS Trust

NIHR Research for Patient Benefit (RfPB) programme

Last reviewed: 04 Nov 2021

CRUK internal database number: 11782

Help and support